GLP Watchdog

Hers vs Nurx

Hers has an open FDA warning letter dated September 9, 2025. Nurx has none. On compounded semaglutide injection, Nurx costs $240 less a year at standing rates: $179 a month against $199 a month at Hers.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hers / Nurx

Hers logo

Hers

6.8/10

Nurx logo

Nurx

4.8/10

FDA warning letters
None on record
Pharmacy
None named in our record
Lowest standing price
$199/moCompounded semaglutide injection
$179/moCompounded semaglutide injection
States
All 50 states
No state list published
Checked
Prices captured Record checked September 2026
Prices captured Record checked September 2026
Visit Hers
Visit Nurx

Neither Hers nor Nurx pays us. Links to them earn nothing. Scores: Hers 6.8, Nurx 4.8. How we are paid

What the record shows

  1. 01

    Hers has an open FDA warning letter dated September 9, 2025. Nurx has none.

  2. 02

    Hers names three pharmacies. Nurx names no compounding pharmacy in our record.

  3. 03

    On compounded semaglutide injection, Nurx costs $240 less a year at standing rates: $179 a month against $199 a month at Hers.

  4. 04

    Only Hers lists a price for brand-name tirzepatide pen. Only Nurx lists a price for compounded tirzepatide injection.

  5. 05

    Hers lists all 50 states. Nurx publishes no state list.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hers

Nurx

Compounded semaglutide injection

$199/mo

$2,388 a year

$179/moLower

$2,148 a year

Compounded tirzepatide injection
Not sold or not priced

$179/mo

$2,148 a year

Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

Not sold or not priced
Price includes
Medication
Not stated
Billed separately
Clinician visits, coaching
Medication, clinician visits
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None
Refunds
No refund guaranteed once the pharmacy has processed an order
The consultation fee is not refunded, even if the request is not approved

Read off each seller’s own pages. Hers: September 28, 2026. Nurx: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hers

6.8/10
  • Sells brand-name tirzepatide pen, which Nurx does not price
  • Names its compounding pharmacy
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
Visit Hers

The case for Nurx

4.8/10
  • No FDA warning letter on record
  • $240 a year less on compounded semaglutide injection
  • Sells compounded tirzepatide injection, which Hers does not price
  • Names no compounding pharmacy
  • Publishes no state list
  • Price leaves out medication and clinician visits
Visit Nurx

Scores

Hers 6.8 · Nurx 4.8 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
3.0

Trust & Safety15%

7.0A
vs
B
4.0

Accessibility10%

10.0A
vs
B
5.0

Support10%

3.0A
vs
B
0.0

The score is the same formula for every seller. Payment does not enter it. Method

Hers vs Nurx: questions

Hers has an open FDA warning letter dated September 9, 2025. Nurx has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Hers names three pharmacies. Nurx names no compounding pharmacy in our record.
Nurx, by $240 a year at standing rates. Hers: $199 a month, about $2,388 a year. Nurx: $179 a month, about $2,148 a year.
Hers states you can cancel at any time; refunds: no refund guaranteed once the pharmacy has processed an order. Nurx states you can cancel at any time; refunds: the consultation fee is not refunded, even if the request is not approved.
Neither Hers nor Nurx pays us. Links to them earn nothing. Scores: Hers 6.8, Nurx 4.8.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks